Harvey RD, Rubinstein WS, Ison G, et al. Impact of broadening clinical trial eligibility criteria for advanced non-small cell lung cancer patients: Real-world analysis. ASCO Annual Meeting 2019, abstract LBA108.
BO-112 plus pembrolizumab bij anti-PD-1-resistent gevorderd melanoom
aug 2025 | Dermato-oncologie, Immuuntherapie